Compare Open Text Corporation (OTEX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Viatris Inc — how do they compare? Open Text Corporation trades at $23.7 (market cap $5.61B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.6× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.82%). Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 23 Days and Viatris Inc for 57 Days on average.
| OTEX | VTRS | |
|---|---|---|
Market Cap | $5.61B | $20.03B |
Volume | 1,197,475 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $39.69 | $18.27 |
52-Week Low | $20.01 | $9.74 |
Typical Hold Time | 23 Days | 57 Days |
Enterprise Value | $10.63B | $32.15B |
Dividend Yield | 4.82% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $23.595, up 1.97% today, showing strong earnings momentum with three consecutive quarterly beats. The stock trades at discounted valuations (P/E 9.01, P/S 1.1) compared to sector peers. Recent corporate actions include a $1 billion senior secured notes offering and strategic AI partnership with Cohere, while technical indicators signal near-term bearish pressure with RSI at overbought levels.
The investment case balances attractive fundamentals against technical headwinds. Strong cloud growth (22.5% bookings growth in fiscal 2026) and improving margins support upside to the $28.30 consensus target, but high debt levels and bearish technical signals warrant caution. The stock offers value opportunity for patient investors despite near-term volatility.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
